Q-omics provides the consensus-scored ATP5F1EP1 profile across patient tissues and cancer cell-line models. ATP5F1EP1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ATP5F1EP1 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, ATP5F1EP1 RNA expression shows 8,417 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UCS, LUSC, and ESCA as cancer lineages where ATP5F1EP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5F1EP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5F1EP1 survival associations across molecular data types. ATP5F1EP1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5F1EP1 RNA expression–survival associations across cancer types. High ATP5F1EP1 expression shows unfavorable associations in UCS, SKCM, CHOL, SARC and COAD, but favorable associations in LGG. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ATP5F1EP1 RNA expression.
This table summarizes ATP5F1EP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5F1EP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5F1EP1 shows lower tumor expression in LUSC, KIRC and THCA and higher tumor expression in PRAD and COAD. The LUSC box plot shows higher ATP5F1EP1 RNA expression in normal versus tumor tissue (log2 FC = −0.172, t-test p < 0.001).
This table shows molecular features associated with ATP5F1EP1 in patient tissues and cancer cell lines. In patient samples, ATP5F1EP1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
